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Abstract
Background
Methylenetetrahydrofolate reductase (MTHFR) acts at an important metabolic point in the
regulation of cellular methylation reaction. It assists in the conversion of 5, 10-methylenete-
trahydrofolate to 5-methyltetrahydrofolate. The latter aids in remethylation of homocysteine
to de novomethionine that is required for DNA synthesis. The objective of this study was to
examine the effect of MTHFR 677 C>T polymorphism on the risk of breast cancer in the In-
dian sub-continent.
Methods and Results
We genotyped 677 C>T locus in 1096 individuals that were classified into cases (N=588)
and controls (N=508). Genotype data were analyzed using chi-square test. No significant
difference was observed in the distribution of genotypes between cases and controls in
north Indian (P = 0.932), south Indian (P = 0.865), and pooled data (P = 0.680). To develop
a consensus regarding the impact of 677C>T polymorphism on breast cancer risk, we also
conducted a meta-analysis on 28031 cases and 31880 controls that were pooled from sixty
one studies. The overall summary estimate upon meta-analysis suggested no significant
correlation between the 677C>T substitution and breast cancer in the dominant model
(Fixed effect model: OR = 0.97, P=0.072, Random effects model: OR = 0.96, P = 0.084) or
the recessive model (Fixed effect model: OR = 1.05, P = 0.089; Random effects model:
OR= 1.08, P= 0.067).
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Conclusion
677 C>T substitution does not affect breast cancer risk in the Indo-European and Dravidian
populations of India. Analysis on pooled data further ruled out association between the 677
C>T polymorphism and breast cancer. Therefore, 677 C>T substitution does not appear to
influence the risk of breast cancer.
Introduction
Breast cancer has become the most common cancer among women with a consistent increase
in frequency. The genetic damage caused by endogenous metabolites and exogenous risks
might explain nature of the disease [1]. The exact causes of breast cancer are unknown, but a
number of factors may contribute to the development of the disease, such as age of menarche
and menopause, diet and exposure to high estrogen levels [2]. The etiology of the disease links
to various genetic and epigenetic processes, including DNA synthesis, methylation, and repair
[3]. Two important mechanisms that might lead to the risk of malignancy are: 1) DNA hypo-
methylation and activation of proto-oncogenes. 2) Misincorporation of uracil during DNA
synthesis, leading to catastrophic DNA repair and chromosome damage [4]. Folate, an impor-
tant dietary component, is found in legumes, green leafy vegetables, and liver, and the role of
this B vitamin involves the transmission of one carbon group to carry out necessary biological
reactions [5]. Deficiency of folate caused by low dietary intake, diminished metabolism or no
auxiliary intake may result in breakage of DNA strands, increased rate of mutagenesis and
changes in the DNAmethylation patterns, ultimately affecting the expression of a number of
genes [6, 7]. Lack of folate is believed to affect the risk of cancer through the processes
described above.
The methylenetetrahydrofolate reductase (MTHFR) gene is mapped to chromosome 1p36.3
and consists of a 2 kbp coding region divided into eleven exons [8]. It plays an important role
in the regulation of cellular methylation by assisting the conversion of 5, 10-methylenetetrahy-
drofolate to 5-methyltetrahydrofolate [9]. The latter aids in the remethylation of homocysteine
to de novo methionine [10], which serves as a precursor for the S-adenosylmethionine, a uni-
versal methyl donor for methylation reactions [11]. It also functions as a coenzyme in purine
and thymidylate synthesis. Two functional polymorphisms in theMTHFR gene, 677C>T
(ala!val) and 1298A>C (glu!ala), have a profound effect on the activity of enzyme, produc-
ing more labile forms with reduced activity [12]. The 677C>T is a common SNP, which con-
verts an alanine to valine at codon 225 of the folate binding site of methylenetetrahydrofolate
reductase [13]. The enzyme with homozygous and heterozygous substitutions exhibit 30% and
65% activity, respectively, in comparison to the wild type [9]. Since low dietary folate intake is
correlated with an increase in the rate of breast cancer, MTHFR 677C>Tmay affect breast can-
cer risk by negatively modifying folate levels [14]. In this case-control study, we investigated if
MTHFR 677 C>T polymorphism affects breast cancer risk. A few meta-analyses have reported
an association between 677 C>T polymorphism and breast cancer risk [10, 15, 16, 17, 18];
however, none of these has addressed the issue using a meticulous plan taking into consider-
ation sensitivity analysis that may significantly affect the outcome. Repeated meta-analysis
using similar strategy does not add new information to the literature. The principal of statistics
that odd observations should not be favoured unless the evidence is very compelling, propelled
us to undertake a stringent statistical approach and sensitivity analysis to critically look into
the relationship between the 677 C>T polymorphism and breast cancer risk.
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Materials and Methods
Case-control study
Subjects. The study and the protocol for sample collection were approved by the Institu-
tional Human Ethics Committee of the King George’s Medical University (KGMU), Lucknow,
India. Informed written consents of the participants were obtained, and no minor subjects
were enrolled in the study. The consent procedure was approved along with the study protocol
by the Institutional Ethics Committee. The study included two ethnically different case-control
groups from the Indian sub-continent. A pre-defined set of recruitment/exclusion protocol
was followed for both groups.
The north Indian group consisted of breast cancer cases (N = 331) and controls (N = 181)
of the Indo-European linguistic group from Uttar Pradesh. The subjects were recruited from
the Department of Surgery and Oncology, KGMU, Lucknow, India. The age of the patients var-
ied from 22 to 90 years with a mean age of 42.11 years (SD 14.21). In this group, 191 cases were
pre-menopausal and 140 were post-menopausal. One hundred fifty-five patients had cancer in
the right breast, 160 patients in the left breast, and only 16 patients in both the breasts. The size
of tumours varied from a minimum of 3 cm3 to a maximum of 1150 cm3 with a mean value of
125.93 cm3 (SD, 324.43). The staging of tumours was done according to the TNM classifica-
tion. Three patients (0.91%) were in stage I, 123 patients (37.16%) were in stage II, 159 patients
(48.03%) were in stage III, and 46 patients (13.89%) were in stage IV. Grading of tumours was
done according to the Bloom-Richardson grading system, where the tumor grade was decided
according to the overall score that a tumor got upon analyzing for the degree of tumor tubule
formation, tumor mitotic activity, and tumor nuclear grade. Healthy controls were recruited
from the out-patient department and staff members of the Department of Surgery and Oncolo-
gy. The controls had no family history of breast cancer and all had undergone a recent mam-
mogram confirming that there was no detectable breast cancer at the time of sampling. Age of
the controls ranged from 28 to 70 years with a mean age of 40 years (SD, 12.40). It was ensured
that patients and controls were enrolled from the populations of same ethnicity.
The south Indian group consisted of patients (N = 257) and controls (N = 327) of the Dra-
vidian linguistic group. The age of the patients ranged from 24 to 82 years with a mean age of
48.32 years (SD 12.25). One hundred and two cases were pre-menopausal and 155 were post-
menopausal. One hundred and nineteen patients had cancer in the right breast, 128 patients in
the left breast, and 10 in both breasts. Size of the tumours varied from a minimum of 6 cm3 to a
maximum of 1310 cm3 with a mean value of 131.23 cm3 (SD, 347.12). The staging of the tu-
mours was done according to the TNM classification. Two patients (0.78%) were found to be
in stage I, 103 patients (40.07%) were in stage II, 142 patients (55.25%) were in stage III, and 10
patients (3.89%) were in stage IV. Ethnically matched controls were recruited from the out-pa-
tient department and staff members who had no family history of breast cancer. The controls
had undergone a recent mammogram confirming absence of breast cancer at the time of sam-
pling. Age of the controls ranged from 32 to 70 years with a mean age of 48 years (SD 12.37).
Further details of the patients and controls are presented in Table 1.
Isolation of genomic DNA. DNA from the peripheral blood samples was extracted using
the phenol-chloroform-isoamyl method. The 677C>T polymorphism was genotyped using the
PCR-RFLP method. Primers in the vicinity of polymorphic site were designed with the GENE-
TOOL software. PCR reactions of 10μl volume were performed in thin walled PCR tubes con-
sisting of 1.0μl of PCR buffer (10X), 1.0μl of dNTPs (10mM), 2.0μl of each of the forward
(5’CATCCCTATTGGCAGGTTACCC3’) and reverse (5’GGGAAGAACTCAGCGAACTCAG3’)
primers, 0.2 μl of Taq DNA polymerase enzyme (Applied Biosystems), and 40ng of genomic
DNA. PCR was carried out in ABI Veriti thermal cycler (Applied Biosystems, USA). PCR
MTHFR 677 C>T and Breast Cancer
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conditions consisted of: denaturation at 95°C for 5 minutes, followed by 35 cycles of denatur-
ation at 95°C for 30 seconds, annealing at 66°C for 30 seconds, polymerization at 72°C for 20
seconds, and a final stage polymerization at 72°C for 7 minutes. The products were digested
withHinfI in a total volume of 10 μl, and the fragments were separated on a 3.0% agarose gel.
The C>T substitution created a restriction site for HinfI that produced fragments of 225bp
and 93bp upon restriction digestion. Representative samples of each genotype were sequenced
by direct DNA sequencing to confirm genotyping results produced by RFLP.
Statistical analysis. Genotype data for control population was studied for fitness in the
Hardy Weinberg Equilibrium (HWE). For this purpose, data was analyzed using calculator
available at http://ihg.gsf.de/cgi-bin/hw/hwa1.pl. Chi-square analysis was done to compare the
genotype data between cases and controls. Data were analyzed using the online statistical tool
available at Vassar Stats online calculator http://faculty.vassar.edu/lowry/VassarStats.html. Sig-
nificance was present if p values were less than 0.05.
Meta-analysis
677C>T in breast cancer has been studied in several ethnic groups, making it valuable to con-
duct a meta-analysis. We have used the Comprehensive Meta Analysis software (version 2) for
this purpose.
Identification of studies. A thorough electronic search of the published literature was
done in ‘Google Scholar (scholar.google.co.in)’, ‘Pubmed (http://www.ncbi.nlm.nih.gov/
pubmed/)’ and ‘Sciencedirect (www.sciencedirect.com)’ databases up to August 2014 as the
publication date, using the following keywords: breast cancer,MTHFR 677C>T polymor-
phism, folate metabolism, and breast cancer in different combinations. Detailed information
regarding data presentation, design and purpose of the study, method of genotyping, and inclu-
sion and exclusion criteria of the subjects were collected. The authors were contacted by e-mail
when published information was inadequate for inclusion in meta-analysis. Meta analyses pub-
lished to date suggest a significant correlation of 677 C>T polymorphism with breast cancer.
Most of these pooled data analysis lack quality control and sensitivity analysis. We have
Table 1. Descriptive data of cases and controls.
North Indian South Indian
Variables Cases Controls Cases Controls
Age (mean±SD) 42.11±14.21 40±12.40 48.32±12.25 48 ± 12.37
BMI (Kg/m2) 22.41+5.87 23.21 ± 5.81 22.19+5.21 22.36± 5.21
Age at menarche (years, mean ± SD) 13.76 ± 1.72 13.54 ± 1.78 13.91 ± 1.18 13.52 ± 1.29
Age at diagnosis for cases or at interview for controls
 30 years 54 16 4 34
31–45 years 134 87 81 114
46–60 years 97 53 117 119
61–75 years 36 17 50 50
76–90 years 10 8 5 10
Family history
Positive 23 0 16 0
Negative 308 181 241 327
Tobacco chewing/smoking habit
Yes 20 10 31 12
No 311 171 226 315
doi:10.1371/journal.pone.0120654.t001
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undertaken a meta-analysis on published data in order to look into the association between
677 C>T polymorphism and breast cancer risk.
Inclusion and exclusion criteria. The inclusion criteria comprised of the following:
i) Each study was an independent case-control study ii) The statistical methods and purpose
of all the studies were similar iii) The given information was enough to calculate the odds ratio
iv) SNP genotyping was done using standard genotyping techniques v) Patients were recruited
in accordance with the standard diagnostic parameters. The exclusion criteria included: the
raw data were unavailable in the article or the authors did not respond after three requests by
e-mail.
Data extraction and statistical approach. The genotype data forMTHFR 677C>T poly-
morphism in relation to breast cancer risk were collected. The required information such as
the first author, ethnicity of the study population, publication year, number of cases and con-
trols, and the frequency of genotypes were gathered.
Statistical analysis. Meta-analysis was conducted using the Comprehensive Meta-Analysis
(CMA) software (version 2), which allows data entry in various formats. The ‘effect size’ was
considered an important criterion to design and interpret the results of meta-analysis that com-
pared CC versus CT+TT genotypes in the dominant model and CC+CT versus TT in the reces-
sive model. We chose the effect size calculated in the form of ‘odds ratio’ for data interpretation.
To calculate heterogeneity quantitatively, Thompson and Higgins classification index, I2, was
taken into account, where a proposed range of 25%, 50%, and 75% is set that corresponds to
low, medium, and high magnitudes of heterogeneity [19]. In the absence of heterogeneity, fixed
effect model using the Mantel-Haenzel method was used for pooled data analysis, else the ran-
dom effects model using the Der Simonian and Laird method was applied [19,20]. High resolu-
tion plot (Forest plot) was produced to estimate the pooled odds ratio and p value. The p values
less than 0.05 were considered statistically significant. The results and the robustness of the
methodology were checked by sensitivity analysis, whereby, studies using small sample size
(<100) in either of the study groups were excluded followed by re-analysis of the data. Sensitivi-
ty analysis aims at identifying the studies that are sensitive enough to significantly bias the re-
sults of pooled analysis. A study may be sensitive due to a variety of reasons, such as the use of
small sample size, large variation in the number of cases and controls analyzed and poor meth-
ods, of which the use of a small sample size is one of the main reasons. The presence of publica-
tion bias was assessed from the funnel plot of precision by log odds ratio method and
statistically tested using Egger’s regression test.
Results
Case—Control study
We have analyzed MTHFR 677 C>T polymorphism in 588 patients and 508 controls
(Table 2). There was no significant difference in the distribution of genotypes between cases
and controls in north Indian (P = 0.932) or south Indian (P = 0.865) groups (Table 2).
Table 2. Genotypes distribution between cases and controls.
Population Cases Controls
CC CT TT CC CT TT
North Indian 229 89 13 127 48 6
South Indian 208 45 4 259 63 5
Total 437 134 17 386 111 11
doi:10.1371/journal.pone.0120654.t002
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Statistical analysis using dominant, co-dominant, and recessive models also detected no signifi-
cant association of c.677C>T polymorphism with breast cancer in north Indian or south Indi-
an groups (Table 3).
Meta—Analysis
Literature search. A total of 141 studies were retrieved upon literature search. After remov-
al of one duplicate [21], 140 records were screened for inclusion in the study. Seventy four of
these were found to be relevant to our study on 677C>T substitution and breast cancer. Eight
studies were excluded due to lack of direct relation to the 677C>T SNP and breast cancer
[22, 23, 24, 25, 26, 27, 28, 29], while six others were excluded as they lacked information re-
quired for meta- analysis [30, 31, 32, 33, 34, 35]. Hence, a total of 60 studies [1, 3–7, 9–13,
36–84] following strict selection criteria were included in the meta-analysis. Along with our
data from India, data for a total of 28031 cases and 31880 controls were included in the meta-
analysis (Fig. 1). Genotype data for all the studies are tabulated in S1 Table.
Pooled analysis. The pooled data showed a low level of heterogeneity based on the
Thompson and Higgins classification index (PHeterogeneity = 0.02, I
2 = 29.55). Meta-analysis sug-
gested no significant association between c.677 C>T and breast cancer risk in the dominant
model (Fixed effect model: OR = 0.97, P = 0.072; Random effects model: OR = 0.96, P = 0.084,
Fig. 2) or the recessive model (Fixed effect model: OR = 1.05, P = 0.089; Random effects model:
OR = 1.08, P = 0.067, figure not shown). In the sub-group analysis, only dominant model was
adopted. In the Caucasian group, the data were homogeneous (Pheterogeneity = 0.19, I
2 = 17.96),
and both Fixed effect (odds ratio = 1.007, P = 0.808) and Random effects models (odds
ratio = 1.009, P = 0.791) suggested a lack of association between the study polymorphism and
the disease risk (Fig. 3). Similarly, the data for East Asians (Pheterogeneity = 0.01, I
2 = 47.21)
showed low level of heterogeneity, and no correlation between c.677 C>T substitution and
breast cancer risk was evident in this group (Fixed effects model: OR = 0.974, P = 0.457 and
Random effects model: OR = 0.933, P = 0.196) (Fig. 4).
Sensitivity analysis based on sample size. To identify sensitive studies affecting the results
of meta-analysis, thirteen studies based on small sample size (<100) in either of the study
groups were excluded [4, 10, 42, 44, 47, 49, 54, 59, 67–69, 74, 81]. Re-analysis of the data
showed more homogeneity (PHeterogeneity = 0.06, I
2 = 25.58), but the substitution did not corre-
late with breast cancer (fixed effect model: odds ratio = 0.975, P = 0.142; random effects model:
odds ratio = 0.970, P = 0.174).
Publication bias. The distribution of studies on the funnel plot was almost symmetrical,
suggesting the absence of publication bias in the overall analysis (S1 Fig.). This was further con-
firmed by Egger’s regression intercept test (P = 0.259). Similarly, a symmetrical distribution of
studies on the funnel plot for the Caucasian population showed absence of bias that was
Table 3. Statistical comparison of genotypes distribution between cases and controls.
Comparisons North Indian South Indian Pooled
OR 95%CI P OR 95%CI P OR 95%CI P
CC vs. (CT+TT) 1.04 0.70–1.55 0.82 0.89 0.59–1.35 0.6 1.09 0.83–1.43 0.52
CC vs. CT 1.02 0.68–1.55 0.88 0.88 0.58–1.35 0.59 1.06 0.80–1.41 0.66
CC vs. TT 1.2 0.44–3.23 0.71 0.99 0.26–3.75 1 1.36 0.63–2.95 0.42
TT vs. CT 0.85 0.30–2.39 0.76 0.89 0.22–3.51 1 0.78 0.35–1.73 0.54
(CC+CT)vs. TT 1.19 0.44–3.19 0.72 1.01 0.27–3.83 1 1.34 0.62–2.89 0.44
CC vs. CT vs. TT - - 0.93 - - 0.86 - - 0.68
doi:10.1371/journal.pone.0120654.t003
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confirmed by Egger’s regression intercept test (P = 0.555). But, the East Asian data also showed
the presence of publication bias, confirmed by the Egger’s regression intercept test (P = 0.017).
Discussion
In the present case-control study on 588 patients and 508 healthy controls, we found no associ-
ation betweenMTHFR 677 C>T gene polymorphism and breast cancer amongst Indian
women. Among other studies on Indian populations, Mir et al. showed that individuals carry-
ing 677 C>T substitution had a 3.5 fold less risk of breast cancer (OR = 3.41, 95%CI = 3.1–3.7,
P<0.02) in a north Indian Caucasian population [59]. On the other hand, Kalyankumar et al.
(2006) and Prasad et al. (2011) reported a lack of association between MTHFR variants and the
risk of breast cancer in south Indian populations [47, 75]. However, Naushad et al. (2010) sug-
gested that the c.677C>T substitution is an independent risk factor for breast cancer in Indian
women of Dravidian ethnicity (OR = 1.74, 95% CI = 1.11–2.73) [72]. The authors suggested
that the risk is related to thermolabile MTHFR enzyme that has the tendency to lose its active
Fig 1. PRISMA flow diagram. The chart shows systematic review of the literature for inclusion/exclusion of
the studies in meta-analysis.
doi:10.1371/journal.pone.0120654.g001
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Fig 2. Meta-analysis. Forest plot on data pooled from all eligible studies. The Z value shows the degree and direction of relationship, wheras the P value
shows the significance of the relationship. The horizontal bar shows the range of OR with a square in the centre, the size of which is directly proportional to
the weight given to each study. The direction of projection of the horizontal bar shows the direction of association.
doi:10.1371/journal.pone.0120654.g002
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dimer form with a reduction in the FAD- binding capacity and loss in specific activity. The
same contrast in the results of case-control studies is seen in other studies on diverse ethnici-
ties; however, a relatively large number of studies support lack of association between 677 C>T
substitution and breast cancer risk. Among studies on Chinese populations, only two out of 13
showed association of 677 C>T substitution with breast cancer risk, whereas all others stated
no such correlation. Ten out of 30 studies on Caucasians reported an association between 677
C>T substitution and breast cancer risk, while others stated lack of such a correlation.
Meta-analysis is a powerful tool to reach consensus on heterogeneous data reported across
studies. At-least seven meta-analyses have been conducted to pool genotype data in order to
reach a consensus. However, interestingly, even meta-analysis on the relation of 677 C>T sub-
stitution with breast cancer has been equally heterogeneous with respect to the analysis models,
stringency, and the outcomes. Zintzaras (2006) compared CC versus TT genotypes in a meta-
analysis on `18 studies (5476 cases and 7336 controls) and found that 677C>T polymorphism
Fig 3. Meta-analysis. Forest plot on data pooled from studies on Caucasian populations. All other parameters are as detailed in Fig. 2.
doi:10.1371/journal.pone.0120654.g003
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and breast cancer are very closely associated with each other in pre-menopausal women [15].
Macis et al. (2007) investigated the relationship by pooling data from 18 case-control studies
and found that 677C>T is strongly associated with breast cancer in both dominant and reces-
sive genetic models [10]. Supporting the conclusions further, Zhang et al. (2010), Qi et al.
(2010), and Liang et al (2013) conducted meta-analyses on 37 studies (15260 cases and 20411
controls), 41 studies (16480 cases and 22388 controls), and 22 studies (6103 cases and 7913
controls), respectively, and reported significant association in comparison of CC versus TT
and in recessive model [16–18]. Rai (2014) and Li et al (2014) conducted meta-analyses on 36
studies (8040 cases and 10008 controls) and 57 studies (25877 cases and 29781 controls), re-
spectively, and found a significant association across all genetic models in Asian population
[85, 86]. Interestingly, all the above described meta-analyses suggested that c.677C>T poly-
morphism is a risk factor for breast cancer.
We undertook a meta-analysis on data pooled from all eligible studies that fitted a strictly
defined inclusion and exclusion criteria. The present meta-analysis pooled data for 28031 cases
and 31880 controls from sixty one studies. Our results suggest thatMTHFR 677C>T polymor-
phism is not associated with the risk of breast cancer in either dominant (P = 0.084) or reces-
sive genetic model (P = 0.067). It must be appreciated that pooling small studies into the meta-
analysis resolves the issues related to sample size, but the biasness introduced by inappropriate
representation of population-wise genotypes ratio would fail to correct. Therefore, we
Fig 4. Meta-analysis. Forest plot on data pooled from studies on East Asian populations. All other parameters are as detailed in Fig. 2.
doi:10.1371/journal.pone.0120654.g004
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conducted a sensitivity analysis after excluding studies using a sample size smaller than 100 in
either of the case/control groups. Interestingly, we failed to detect an association between 677
C>T substitution and breast cancer, suggesting robustness of the method used in pooled analy-
sis. Lack of publication bias further suggests that the results have not been influenced by any
missing study. Analysis ethnicity-wise was considered so as to uncover the association in a par-
ticular ethnic population. A majority of the published studies were conducted on Caucasian
and East-Asian populations with a small number on other populations. Therefore, we under-
took two sub-analysis on Caucasian and East-Asian data; however, lack of a correlation be-
tween 677 C>T substitution and breast cancer risk was consistent. It is interesting to note the
reported association of this substitution with breast cancer in a number of case-control studies;
however, it has not been suggested what could be the mechanism leading to cancer in relatively
poor one carbon metabolism as the nutritional deficiencies have not been reported to directly
raise cancer risk.
In conclusion, while a majority of the case-control studies deny an association between the
677 C>T polymorphism and breast cancer, meta-analyses till date have consistently supported
existence of an association. Our stringent statistical approach and thorough sensitivity analyses
have suggested that 677C>T does not affect breast cancer risk. About 50% of the studies pooled
in this analysis had been undertaken on populations of Caucasian ethnicity and 30% on East
Asian populations. Therefore, our results would be more relevant to the populations of these
ethnicities and caution must be ensured while extrapolating them to other populations.
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S1 Table. Studies included in the meta-analysis. All the studies that were included in the
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